Nutlin-3a

For research use only.

Catalog No.S8059 Synonyms: (-)-Nutlin-3

38 publications

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Nutlin-3a has been cited by 38 publications

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILnZ5pKSzVyPUCuOlEzOzdizszN MlvRV2FPT0WU
H4 MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3G0Z2lEPTB;MD62OlI5KM7:TR?= NUfxVpNEW0GQR1XS
PA-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwOEewPVYh|ryP MmrVV2FPT0WU
NKM-1 NVTmWXVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mke5TWM2OD1zLkC0PVMyKM7:TR?= MV;TRW5ITVJ?
NEC8 NXfXXlRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwMkG1O|Ih|ryP MV3TRW5ITVJ?
EoL-1-cell MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLtTWM2OD1zLkK2O|AyKM7:TR?= MmXSV2FPT0WU
K5 NYr4cXo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vCPGlEPTB;MT60NlA4OiEQvF2= M1i5WXNCVkeHUh?=
QIMR-WIL NFjiSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPFWlZyUUN3ME2xMlYxQDV2IN88US=> M2WzW3NCVkeHUh?=
MOLT-16 NFrKUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonVTWM2OD1zLke4OlA1KM7:TR?= Mk[2V2FPT0WU
CHP-212 NX74VZBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3S0dGlEPTB;MT64NVM3QSEQvF2= NHXvcpBUSU6JRWK=
CTB-1 Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPVeJlsUUN3ME2yMlAzOjR4IN88US=> NHW2OnVUSU6JRWK=
MOLT-4 MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf5TWM2OD1{LkOyPFU{KM7:TR?= Mn6xV2FPT0WU
A101D MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\RXGlEPTB;Mj6zOVAyKM7:TR?= M3\0eXNCVkeHUh?=
DOHH-2 M2fncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ToZWlEPTB;Mj60NlI4QSEQvF2= M3LHXnNCVkeHUh?=
ES4 NF20XGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHzTJhKSzVyPUKuOFMyPTVizszN NUnsTnl2W0GQR1XS
SW780 NVnK[lRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTJwNUC4PFMh|ryP MofMV2FPT0WU
VA-ES-BJ NXLoOW1FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPJTWM2OD1{LkW0NVEh|ryP MoLlV2FPT0WU
RPMI-8866 M{\ITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzITWM2OD1{LkW2NlE1KM7:TR?= M4\uRXNCVkeHUh?=
ML-2 NFHYVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTJwNU[1O|Yh|ryP M3jI[XNCVkeHUh?=
MSTO-211H NGD0T2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH[0NJFKSzVyPUKuOVc1PTFizszN NGC4NlVUSU6JRWK=
JVM-3 NGm3SHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\tVFNKSzVyPUKuOVk{OjRizszN NXnLWYtUW0GQR1XS
A3-KAW NIPxVlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2POOWlEPTB;Mj62NVgyQCEQvF2= NFLSe4pUSU6JRWK=
DK-MG NXriWIpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHJe4lKSzVyPUKuOlI1PzFizszN NXjnNodUW0GQR1XS
LNCaP-Clone-FGC NHfsSpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jMfWlEPTB;Mj62OFMyQCEQvF2= MUTTRW5ITVJ?
HT-144 NUnvZY0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fNemlEPTB;Mj62OFU4PyEQvF2= NFmzTFRUSU6JRWK=
NB69 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJwNkWzN|Qh|ryP MnvpV2FPT0WU
A172 NXq1Z4tNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITwRoNKSzVyPUKuOlc2QDhizszN M1nyfXNCVkeHUh?=
RS4-11 MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXxTWM2OD1{LkeyOFA4KM7:TR?= NFL0WIZUSU6JRWK=
DU-4475 M4PtZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HrUWlEPTB;Mj63PVUxOiEQvF2= NH3YbolUSU6JRWK=
SJSA-1 NF[0WlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJwOEK1OVYh|ryP MUPTRW5ITVJ?
BV-173 M4P3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJwOES0N|kh|ryP M4HQbXNCVkeHUh?=
U-2-OS M{ixXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnsWJRbUUN3ME2yMlkyODdizszN MkLpV2FPT0WU
CHP-134 NHnaWXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS3OYVKSzVyPUKuPVM5QDJizszN NXrRfopKW0GQR1XS
D-502MG NVTRXGVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7hTGxKSzVyPUKuPVcyPTRizszN NVnPO5RDW0GQR1XS
KS-1 NHjxR4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjTV3VKSzVyPUOuNFE3OjNizszN NILQT3pUSU6JRWK=
A204 M4O4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLQdmxNUUN3ME2zMlA2PTh6IN88US=> NEHWXGhUSU6JRWK=
KGN MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXL2Z2lVUUN3ME2zMlA5PDl4IN88US=> M1TONHNCVkeHUh?=
NCI-H292 NWjxTGd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7JTWM2OD1|LkGyNFI5KM7:TR?= NX7XTY9RW0GQR1XS
CAKI-1 NV6xdGh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3qyUGlEPTB;Mz6xNlY6PCEQvF2= NHPjbWNUSU6JRWK=
C2BBe1 NFy4WGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P2dmlEPTB;Mz6xO|AzPiEQvF2= NHvXUWlUSU6JRWK=
NB10 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXBTWM2OD1|LkKwPVY3KM7:TR?= MUfTRW5ITVJ?
MHH-NB-11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTNwMk[4Nlch|ryP NU\sSoQxW0GQR1XS
NCI-SNU-1 MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTwOnREUUN3ME2zMlI4QDR|IN88US=> NGXue3BUSU6JRWK=
HCT-116 Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLXWFhKSzVyPUOuN|A{OzVizszN M4r3cnNCVkeHUh?=
G-401 NYO5THhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHEdJZKSzVyPUOuN|Y{OjJizszN NH[5UJVUSU6JRWK=
MN-60 NX\TdlNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXxb5pNUUN3ME2zMlQ1ODl{IN88US=> MY\TRW5ITVJ?
SW982 NIe4WJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\HNmlEPTB;Mz61NFg1QCEQvF2= NU\tR3B2W0GQR1XS
RKO MmfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTNwNUO5N|Yh|ryP NELUS4ZUSU6JRWK=
D-283MED MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrNT4VXUUN3ME2zMlU4QTh4IN88US=> NGrCZ3RUSU6JRWK=
LB996-RCC NVWwfI13T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX23flE4UUN3ME2zMlYzPTV6IN88US=> NFHxOXBUSU6JRWK=
A549 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkO0TWM2OD1|Lk[zOVUzKM7:TR?= MYfTRW5ITVJ?
LB2241-RCC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP0WWdqUUN3ME2zMlY2PzB6IN88US=> MmLsV2FPT0WU
SK-HEP-1 NFjkcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTNwN{SyPVch|ryP NVG0dGY4W0GQR1XS
G-402 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTNwOEC4N|Ih|ryP MlzqV2FPT0WU
GOTO M4fWdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTNwOESzN|Mh|ryP NH7VbIxUSU6JRWK=
LOXIMVI M3rlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjudGM6UUN3ME2zMlg2Pjd3IN88US=> NGm4cHVUSU6JRWK=
NH-12 M{TaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWCyfpVvUUN3ME20MlAyQTV7IN88US=> M2PmT3NCVkeHUh?=
CTV-1 NF[xOXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PqV2lEPTB;ND6wO|k4OyEQvF2= NHLJN5dUSU6JRWK=
CP50-MEL-B MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP4TWM2OD12LkK0N|kzKM7:TR?= M2PyUnNCVkeHUh?=
RH-18 NY\XbnB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT6[Zk1UUN3ME20MlI4PzB4IN88US=> NUT3fVJ6W0GQR1XS
NB17 M2P3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1P6T2lEPTB;ND6zNVc3QCEQvF2= Mn20V2FPT0WU
A375 NXrJOFdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PkV2lEPTB;ND6zN|UzPCEQvF2= MV\TRW5ITVJ?
IST-MES1 NYDhR4xWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTRwNEG0NVEh|ryP MX3TRW5ITVJ?
MZ2-MEL NGTyOI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTRwNUCxOVUh|ryP M1XPOHNCVkeHUh?=
CAL-54 M1rUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\yNpRKSzVyPUSuOVMxOTlizszN M1vEe3NCVkeHUh?=
NCI-H28 NIm2epNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy5O4pKSzVyPUSuOlI4OTdizszN M3rWN3NCVkeHUh?=
D-247MG M{Ppdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPLOmEyUUN3ME20Mlc2ODd{IN88US=> MWDTRW5ITVJ?
NCI-H460 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX0clNKSzVyPUSuPVEyOjdizszN NHyze4dUSU6JRWK=
MCF7 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTVwNESyOFQh|ryP M2rtbnNCVkeHUh?=
697 NXjaU281T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[3WJNKSzVyPUWuOFQ2PSEQvF2= NYnDdVZKW0GQR1XS
ONS-76 M3fFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTVwNUewNFkh|ryP MWHTRW5ITVJ?
C32 M1S3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvlblhbUUN3ME21MlYxODJ7IN88US=> MULTRW5ITVJ?
OS-RC-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f4Z2lEPTB;NT63N|g5PyEQvF2= NXfNW|VrW0GQR1XS
MEL-HO NUn2dmY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTVwOEW2Olch|ryP NEXFRoxUSU6JRWK=
LoVo NVTzepBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TENmlEPTB;Nj6wNVYzPCEQvF2= Moj4V2FPT0WU
AGS M4jNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe3ZYVKSzVyPU[uNVQ5OjhizszN NVPwZo1XW0GQR1XS
GI-ME-N NHrOWZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3aTWM2OD14LkKyOFIyKM7:TR?= Mm\mV2FPT0WU
H-EMC-SS NX7iW|ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHBepdKSzVyPU[uN|g3KM7:TR?= NGnoSXJUSU6JRWK=
RVH-421 NWXvXVN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LHPWlEPTB;Nj60NlQzQCEQvF2= Mm\CV2FPT0WU
SW954 M2P0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTqPFhKSzVyPU[uOVU2PzJizszN NUDXR|VLW0GQR1XS
NB5 NXHlRnNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnoN29KSzVyPU[uOVYyQDNizszN MnfCV2FPT0WU
NCI-H2122 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTZwNUi3PVMh|ryP MV3TRW5ITVJ?
AM-38 NYXHTZJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\ifWlEPTB;Nj63OVY{QSEQvF2= MoHiV2FPT0WU
KNS-81-FD MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TNT2lEPTB;Nj63OlQ6PCEQvF2= M1z5N3NCVkeHUh?=
LS-513 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTZwN{mwNlYh|ryP NVPXXos{W0GQR1XS
A427 M{TVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLXTWM2OD14Lki3PFI6KM7:TR?= MVnTRW5ITVJ?
WM-115 NFjuUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXV[4tGUUN3ME22Mlk{OjNizszN NVjseoNMW0GQR1XS
COLO-829 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLjWoV3UUN3ME23MlI1OTh6IN88US=> MnvYV2FPT0WU
NCI-H1650 NXTUPGh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLhTWM2OD15LkO5NlI5KM7:TR?= M2DncHNCVkeHUh?=
NCI-H358 M4qzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTdwNES4O|kh|ryP Mn3xV2FPT0WU
HT-1080 NEfIRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLsXmJKSzVyPUeuOFgzPTRizszN NEf0R25USU6JRWK=
HCC2218 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7GRYxRUUN3ME23MlYzQTdizszN MYTTRW5ITVJ?
NCI-H661 NVPWW4ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;JRXlXUUN3ME23Mlg4ODZ7IN88US=> Mme0V2FPT0WU
KM-H2 NWfIcXdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO3TWM2OD15Lki4Olk1KM7:TR?= NU\QXWtKW0GQR1XS
RPMI-2650 NIfodpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTdwOUS0NVQh|ryP NX7uenBzW0GQR1XS
NCI-H226 Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfLSJZGUUN3ME24MlIyOTJ{IN88US=> NW\tdod[W0GQR1XS
MKN45 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrJRoFKSzVyPUiuNlY3ODJizszN M4O1RnNCVkeHUh?=
D-392MG M4DXR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3KV4puUUN3ME24MlUzPzJ{IN88US=> NEnndXhUSU6JRWK=
RCC10RGB M2jJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrVTYRPUUN3ME24Mlg3Pjl3IN88US=> M4SyU3NCVkeHUh?=
CAL-51 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLCTWM2OD17LkGwNlUyKM7:TR?= NHq1SFBUSU6JRWK=
COLO-678 M1nKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnhNnJKSzVyPUmuN|I5OTFizszN NVrGR5B1W0GQR1XS
SK-MEL-24 NEfBcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTlwNUW4OVYh|ryP M3HmfXNCVkeHUh?=
SK-MEL-30 M4P0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[wemlEPTB;OT65OFQ4PiEQvF2= NXfYTpFEW0GQR1XS
MMAC-SF NH\obotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmKzTWM2OD1zMD6zPVYyKM7:TR?= MUnTRW5ITVJ?
NTERA-S-cl-D1 NWSwcHhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rIUmlEPTB;MUCuOlUxQCEQvF2= M2P5N3NCVkeHUh?=
NB12 NH3NUW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj4VXBKSzVyPUGxMlUxOyEQvF2= MU\TRW5ITVJ?
UACC-257 Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPVeVg{UUN3ME2xNU45Pjl3IN88US=> MkTMV2FPT0WU
LAN-6 M37Z[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDETWM2OD1zMT65PVI5KM7:TR?= NHTFUpVUSU6JRWK=
SW1573 MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O4O2lEPTB;MUKuN|A5PiEQvF2= M1:zV3NCVkeHUh?=
NMC-G1 NEXPOY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF{LkSxO|Uh|ryP MWHTRW5ITVJ?
SHP-77 NWDwVZg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLZdJZKSzVyPUGyMlU2PzRizszN NI\nXmtUSU6JRWK=
IGROV-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\WW5pKSzVyPUGyMlY2PzNizszN NGLkN3lUSU6JRWK=
22RV1 NIC5WWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTF{LkiwOVkh|ryP M3;CSXNCVkeHUh?=
SK-MEL-3 NH\pTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XOO2lEPTB;MUOuN|k4OyEQvF2= NIfxTlNUSU6JRWK=
NCI-H1563 NXLxSm8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{n0e2lEPTB;MUOuOFIxOiEQvF2= NGLyfZBUSU6JRWK=
IGR-1 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF2LkCzOFch|ryP MkjWV2FPT0WU
EW-3 NXTye3U1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEP1Z5RKSzVyPUG0MlE3OzlizszN NUPOZlhmW0GQR1XS
JEG-3 MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjqTWM2OD1zND60PVU{KM7:TR?= M1u4O3NCVkeHUh?=
ES3 M3nXRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL1R5lKSzVyPUG0MlY2PjJizszN Mmi3V2FPT0WU
MDA-MB-175-VII M{TJVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml6yTWM2OD1zND63NVEyKM7:TR?= MlTlV2FPT0WU
P30-OHK Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFO1WXNKSzVyPUG1MlA1QTZizszN M{T2U3NCVkeHUh?=
GP5d Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn5bmRnUUN3ME2xOU4yPDZ4IN88US=> M2fGS3NCVkeHUh?=
HMV-II MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTF3LkOzN|Mh|ryP NXvBemw2W0GQR1XS
COLO-679 MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\aRWlEPTB;MUWuOVAyKM7:TR?= M2j6V3NCVkeHUh?=
JAR MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnkTWM2OD1zNT63NlA2KM7:TR?= Mm\xV2FPT0WU
NCI-H1666 MnX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfVTZFKSzVyPUG1Mlk{QTlizszN NGrqN4RUSU6JRWK=
SW48 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPPO4VKSzVyPUG1Mlk2OTZizszN NHTrdWtUSU6JRWK=
NCI-H720 NXLLbFdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXSeI5KSzVyPUG1Mlk6QDlizszN NW\WNW5rW0GQR1XS
HT-1197 NHfwdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPDcVNKSzVyPUG2MlA{PTJizszN MYjTRW5ITVJ?
HL-60 M1jjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zLe2lEPTB;MU[uNFM5PCEQvF2= NEKxdGVUSU6JRWK=
BEN M4\2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLyTWM2OD1zNj61OlM5KM7:TR?= Moi1V2FPT0WU
HAL-01 Mmi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrGb41DUUN3ME2xOk45QTB7IN88US=> M2jaeHNCVkeHUh?=
SW900 NYXOdow4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nxcGlEPTB;MU[uPVE{OiEQvF2= NHu0d|RUSU6JRWK=
SBC-1 NVPOdY81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jiPWlEPTB;MUeuOVQzQSEQvF2= M1:0XHNCVkeHUh?=
SH-4 M4S1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjSWndKSzVyPUG3MlU5PDFizszN MYTTRW5ITVJ?
UACC-62 NF:1d5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILsOlJKSzVyPUG3Mlc3OzdizszN MUnTRW5ITVJ?
BHT-101 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTF7Lki3NFUh|ryP M{KyU3NCVkeHUh?=
DB NVrafZFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\0V3RKSzVyPUKxMlU3PDlizszN MV\TRW5ITVJ?
SK-MEL-1 M3vuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X6[GlEPTB;MkGuOVg4OiEQvF2= MlfOV2FPT0WU
NCI-H747 MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[1WWlEPTB;MkKuO|M4QSEQvF2= MmHwV2FPT0WU
SK-LU-1 MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPvTWM2OD1{Mz6zOVI1KM7:TR?= MmPYV2FPT0WU
KG-1 MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rHbWlEPTB;MkOuOFk1PiEQvF2= M2LSPHNCVkeHUh?=
LXF-289 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7pS2ZWUUN3ME2yN{44OTRizszN NVLrdI43W0GQR1XS
HCC1954 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJ2Lki4OFQh|ryP NXjJTJkyW0GQR1XS
Ramos-2G6-4C10 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPXd45KSzVyPUK2MlQ6QDFizszN M125ZnNCVkeHUh?=
DBTRG-05MG MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHQdlJKSzVyPUK2MlY1QDhizszN M{DVVHNCVkeHUh?=
NCI-H2052 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7iUotKSzVyPUK3MlU3QDRizszN MUXTRW5ITVJ?
RMG-I NWO4UpdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf1eIFKSzVyPUK5MlQyOzlizszN MomzV2FPT0WU
H9 NVKybXNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfhbJdKSzVyPUOxMlMxODhizszN NFzFdWZUSU6JRWK=
GR-ST NInDfW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXUSmk4UUN3ME2zNk41PDV|IN88US=> Ml;QV2FPT0WU
Mo-T MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPnU45JUUN3ME2zNk42ODR4IN88US=> NEKxT|dUSU6JRWK=
SW1088 NUS5ZVNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3frUWlEPTB;M{KuPVgxOSEQvF2= Mo\JV2FPT0WU
LB2518-MEL NXrFT3pTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7STWM2OD1|Mz6wO|k4KM7:TR?= NXHxVXZuW0GQR1XS
NCI-H82 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDZOoRKSzVyPUOzMlE3PjFizszN MW\TRW5ITVJ?
LAMA-84 MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTN2Lk[wO|Mh|ryP MoXPV2FPT0WU
KYSE-450 NHXGRWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLtR|FrUUN3ME2zOE43Pzd4IN88US=> NGTNXGxUSU6JRWK=
LU-99A NXLBdph6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofSTWM2OD1|NT6wNFA4KM7:TR?= NH7pTmNUSU6JRWK=
BE-13 M4rmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnxbHpiUUN3ME2zOU43PTR3IN88US=> MlPSV2FPT0WU
GAK MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnSdXJKSzVyPUO1MlY6PSEQvF2= NXrpflYzW0GQR1XS
NCI-H1573 M3nIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjiZ2RKSzVyPUO1Mlg5OThizszN NYPTVYNSW0GQR1XS
AsPC-1 NVroT3NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULjcIF4UUN3ME2zOk4yPTJ5IN88US=> M3zuOHNCVkeHUh?=
HDLM-2 NIHXTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHHdWM1UUN3ME2zOk4{OTZizszN MUXTRW5ITVJ?
NCI-H441 NHXsXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTN5LkC2PVEh|ryP MVfTRW5ITVJ?
CAL-27 MmL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrlZ2hmUUN3ME2zO{44OjNzIN88US=> M3X5cXNCVkeHUh?=
OVCAR-3 NUfucFUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT6TWM2OD1|OT6zNVgyKM7:TR?= MlfvV2FPT0WU
RPMI-8226 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P0[2lEPTB;M{muOVk5KM7:TR?= M2DHUnNCVkeHUh?=
EFO-21 NGe3dGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XWXWlEPTB;NECuOVgyPCEQvF2= NVLsW|ZtW0GQR1XS
SNU-C2B NIHFOo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHwWnBDUUN3ME20NU42ODh2IN88US=> M4DoTXNCVkeHUh?=
VM-CUB-1 NWTJVpMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHOO3I{UUN3ME20N{45ODN5IN88US=> NEXhcJNUSU6JRWK=
NCI-H2087 NH:1WGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4qwR2lEPTB;NEWuNFI{OyEQvF2= MXXTRW5ITVJ?
EW-16 M2H2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWntRmt[UUN3ME20Ok4{OTN5IN88US=> MYTTRW5ITVJ?
SK-N-AS Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPZTWM2OD12Nj63NVY4KM7:TR?= Mmm0V2FPT0WU
COR-L105 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLHTWM2OD12Nj64PFU4KM7:TR?= NHuxfWhUSU6JRWK=
DEL M1vRZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TlemlEPTB;NEiuNFQzQSEQvF2= M{K1VXNCVkeHUh?=
JVM-2 NWHNd41pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHsXndmUUN3ME20PE4xPTV6IN88US=> NFTNOm9USU6JRWK=
KARPAS-45 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTR7LkS1N|gh|ryP NWW3fWdyW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / MDM2 / p21 / Bax / Bak / Noxa / cleaved caspase / pro-caspase; 

PubMed: 16014563     


Expression of apoptosis- and cell-cycle–associated proteins in OCI-AML-3 cells, which were treated with 5 μM Nutlin-3a for the indicated times. Nutlin-3a induced increased protein expression of p53, MDM2, and p21 in OCI-AML-3 cells in a time-dependent fashion. Nutlin-3a induced Noxa, a BH3-only member of the Bcl-2 family, followed by caspase activation. β-actin was used to confirm equal loading of proteins. Arrowheads indicate cleared caspases.

BMI-1; 

PubMed: 26887044     


Western blot analysis of BMI-1 and actin was performed in BV-173, SUP-B15, NALM-6, NALM-19 and REH cell lines after 24 hours treatment with increasing concentrations of Nutlin-3a (1 μM, 2 μM, 5 μM) and with DMSO control. 

p53-Ser15 / p53-Ser37 / p53-Lys382 / MDM2 / CDC2 / PLK1 / HSC70; 

PubMed: 23666059     


Expression of the indicated proteins in whole-cell lysates of cells treated for 96 h with 50 μM resveratrol (R), 5 μM nutlin-3a (N), or co-treated with both substances (RN).

16014563 26887044 23666059
Immunofluorescence
p-p21 / β-actin; 

PubMed: 31083332     


Cells were treated with fluoride (5 mM) with/without Nutlin-3a for 24 h. p-p21 (green), nucleus (DAPI; blue) and β-actin (red) expression were detected by immunocytochemistry. Nutlin-3a addition augmented p-p21 expression compared to NaF treatment alone.

P53; 

PubMed: 21394100     


At 12 h following treatment with nutlin-3a, DoHH2 and MCA cells had increased levels of p53 visualized by immunofluorescence. p53 localization was predominantly nuclear. The 4',6-diamidino-2-phenylindole was used as counterstain of the nuclei.

Ac-p300; 

PubMed: 30240745     


HepG2 cells were treated with 5 μM Nutlin-3a for 24 hr, and the levels of Ac-p300 and p53 were assessed by co-immunofluorescence. Fluorescence intensity of Ac-p300 in control cells versus Nutlin-3a-treated cells have been quantified (represented as mean ± SD, unpaired two-tailed Student's t test, n = 50 of three independent experiments). Scale bar, 10 μm.

31083332 21394100 30240745
Growth inhibition assay
Cell viability; 

PubMed: 26248031     


All 15 cell lines were plated in 96-well plates. After 24h, media was exchanged and cells were treated with incremental concentrations of Nutlin-3a (1 μM, 5 μM, 10 μM, 25 μM, 50 μM, and 70 μM). After 72h of Nutlin-3a treatment, cell viability was measured by WST assay and compared to untreated control.

26248031
In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
- Collapse

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
- Collapse
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: SJSA-1 xenograft
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Water Insoluble
Ethanol '100 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between S1061 (Nutlin-3) and S8059 (Nutlin-3a)?

  • Answer:

    S1061 is a racemic mixture of Nutlin3a and Nutlin3b. s8059 is the active enantiomer of Nutlin3.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID